The Emerging Role of Genetic Testing in Colorectal Cancer
Pashtoon M. Kasi, MD, MBBS, MS, discusses how genetic testing is underutilized in colorectal cancer, despite its ability to guide treatment dosing and adjustment based on the mutations or variations within a patient.
Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses how genetic testing is underutilized in colorectal cancer (CRC), despite its ability to guide treatment dosing and adjustment based on the mutations or variations within a patient.
In CRC, specific genes are known to metabolize 5-fluorouracil, capecitabine, or irinotecan. Historical analyses have also shown that patients do much worse in regard to toxicities when given chemotherapy if they harbor a gene abberration, but Kasi says the frequency in which this aberration appears is underestimated.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
